JP2024507318A5 - - Google Patents
Info
- Publication number
- JP2024507318A5 JP2024507318A5 JP2023536959A JP2023536959A JP2024507318A5 JP 2024507318 A5 JP2024507318 A5 JP 2024507318A5 JP 2023536959 A JP2023536959 A JP 2023536959A JP 2023536959 A JP2023536959 A JP 2023536959A JP 2024507318 A5 JP2024507318 A5 JP 2024507318A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- heavy chain
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063127994P | 2020-12-18 | 2020-12-18 | |
| US63/127,994 | 2020-12-18 | ||
| US202063128804P | 2020-12-21 | 2020-12-21 | |
| US63/128,804 | 2020-12-21 | ||
| PCT/US2021/064223 WO2022133325A2 (en) | 2020-12-18 | 2021-12-17 | Tnf alpha and ngf antibodies for veterinary use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024507318A JP2024507318A (ja) | 2024-02-19 |
| JP2024507318A5 true JP2024507318A5 (enExample) | 2024-12-25 |
Family
ID=82060113
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023536959A Pending JP2024507318A (ja) | 2020-12-18 | 2021-12-17 | 動物用のｔｎｆアルファ及びｎｇｆ抗体 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240101715A1 (enExample) |
| EP (1) | EP4263603A4 (enExample) |
| JP (1) | JP2024507318A (enExample) |
| KR (1) | KR20230154300A (enExample) |
| AU (1) | AU2021401815A1 (enExample) |
| CA (1) | CA3202331A1 (enExample) |
| MX (1) | MX2023007303A (enExample) |
| WO (1) | WO2022133325A2 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017189805A1 (en) | 2016-04-27 | 2017-11-02 | Abbvie Inc. | Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE239041T1 (de) * | 1996-02-09 | 2003-05-15 | Basf Ag | Humane antikörper welche an humanen tnfalpha binden |
| US8877688B2 (en) * | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
| US8822645B2 (en) * | 2008-07-08 | 2014-09-02 | Abbvie Inc. | Prostaglandin E2 dual variable domain immunoglobulins and uses thereof |
| ES2665954T3 (es) * | 2010-08-19 | 2018-04-30 | Zoetis Belgium S.A. | Anticuerpos anti-NGF y su uso |
| EP2751139A1 (en) * | 2011-08-30 | 2014-07-09 | NVIP Pty Ltd | Caninised tumour necrosis factor antibodies and methods of using the same |
| WO2020186090A2 (en) * | 2019-03-12 | 2020-09-17 | The Regents Of The University Of California | Activatable specific binding member complexes, and methods of making and using same |
-
2021
- 2021-12-17 CA CA3202331A patent/CA3202331A1/en active Pending
- 2021-12-17 WO PCT/US2021/064223 patent/WO2022133325A2/en not_active Ceased
- 2021-12-17 US US18/258,071 patent/US20240101715A1/en active Pending
- 2021-12-17 JP JP2023536959A patent/JP2024507318A/ja active Pending
- 2021-12-17 KR KR1020237024377A patent/KR20230154300A/ko active Pending
- 2021-12-17 AU AU2021401815A patent/AU2021401815A1/en active Pending
- 2021-12-17 EP EP21907966.2A patent/EP4263603A4/en active Pending
- 2021-12-17 MX MX2023007303A patent/MX2023007303A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9475872B2 (en) | Nucleic acid molecules encoding moonoclonal antibodies speceific for IL17F | |
| US8945560B1 (en) | Method of treating rheumatoid arthritis using antibody to IL6R | |
| JP2020511123A5 (enExample) | ||
| JP6720079B2 (ja) | 対象とするヒト標的に特異的に結合するリガンド | |
| US8980273B1 (en) | Method of treating atopic dermatitis or asthma using antibody to IL4RA | |
| KR20120060877A (ko) | 이원 가변 도메인 면역글로불린 및 이의 용도 | |
| JP2019531273A5 (enExample) | ||
| KR20120047274A (ko) | 이원 가변 도메인 면역글로불린 및 이의 용도 | |
| KR20130043168A (ko) | 이원 가변 도메인 면역글로불린 및 이의 용도 | |
| KR20130118892A (ko) | 이원 가변 도메인 면역글로불린 및 이의 용도 | |
| US20160002343A1 (en) | Blood-brain barrier (bbb) penetrating dual specific binding proteins for treating brain and neurological diseases | |
| KR20130105601A (ko) | 이원 가변 도메인 면역글로불린 및 이의 용도 | |
| KR20130139884A (ko) | 이원 가변 도메인 면역글로불린 및 이의 용도 | |
| KR20110014607A (ko) | 이원 가변 도메인 면역글로불린 및 이의 용도 | |
| KR20110016959A (ko) | 이원 가변 도메인 면역글로불린 및 이의 용도 | |
| KR20130133247A (ko) | Ｉｌ-1-알파 및 -베타 이특이적 이원 가변 도메인 면역글로불린 및 이의 용도 | |
| KR20110031369A (ko) | 프로스타글란딘 ｅ2 이원 가변 도메인 면역글로불린 및 이의 용도 | |
| JP2016501881A (ja) | 血液脳関門（ｂｂｂ）を透過する二重特異性結合タンパク質 | |
| KR20140015139A (ko) | 이원 가변 도메인 면역글로불린 및 이의 용도 | |
| KR20140015145A (ko) | 이원 가변 도메인 면역글로불린 및 이의 용도 | |
| JP2020504076A5 (enExample) | ||
| US9017678B1 (en) | Method of treating rheumatoid arthritis using antibody to IL6R | |
| JP2023524643A5 (enExample) | ||
| JP2022545259A5 (enExample) | ||
| JP2022517324A5 (enExample) |